Skip to main content
. 2024 Feb 12;14:1258991. doi: 10.3389/fonc.2024.1258991

Table 2B.

Estimated incidence of cardiovascular adverse events associated with immune checkpoint inhibitor therapy based on a safety meta-analysis (35, 36).

Cardiovascular Adverse Event Summary Incidence (95% CI)
Myocarditis 0.3% (0.2 – 0.5%)
Pericarditis 0.8% (0.6 – 1.1%)
Arrhythmias 1%
Heart Failure 0.9% (0.7 – 1.1%)
Myocardial Infarction 0.7% (0.6 – 0.9%)
Ischemic Stroke 0.9% (0.7% – 1.1%)
Venous Thromboembolism 12.9%
Dyslipidemia 1.9% (0.7 – 5.4%)